Class, Biotech Co. Propose $10.65M Deal To End Merger Suit
Former Asterias Biotherapeutics stockholders have reached a $10.65 million deal to settle a 3-year-old Delaware Chancery Court class action challenging the company's November 2018 stock-for-stock merger agreement with allegedly controlling investor...To view the full article, register now.
Already a subscriber? Click here to view full article